Future studies will further explore the relationship between DCE-MRI radiomic features and treatment response or prognosis in HER2-positive breast cancer patients with different CD8+TILs levels in the multi-center to enhance the clinical applicability of our findings. This evidence concerns the gene CD8A and breast carcinoma.